Paratope-PLUS™ involves mutating each residue of an antibody's CDRs (Complementarity Determining Regions) to all 19 other amino acids, identifying every variant that retains or enhances function.

The first anti-amyloid monoclonal antibody -- and the first drug of any ... on the 18-point Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale over 18 weeks. Mean baseline score was about ...

Acumen Pharmaceuticals has concluded enrolment for its multi-centre, double-blind Phase II ALTITUDE-AD trial of humanised ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

Sino Biological delivers high-quality monoclonal antibody humanization services with a high degree of success (>90%) utilizing complementarity-determining region (CDR) grafting technology and ...

CDR-Life develops highly targeted T cell engagers ... demonstrates the potential of our antibody-derived molecules. Backed by leading cross-Atlantic investors, our team is committed to bringing ...

BI 771716, engineered using CDR-Life's proprietary technology and developed by Boehringer Ingelheim, represents a potential breakthrough in retinal therapy. Its unique antibody fragment design ...

Additionally, it provides LucinaTech, an antibody humanization to identify framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; antibody ...

ZÜRICH, March 25, 2025--(BUSINESS WIRE)--CDR-Life today announced the expansion of its product portfolio with the nomination of CDR111 as a new clinical candidate for autoimmune diseases along ...